Techstars is a global platform that provides investment and innovation. Through the Techstars Worldwide Entrepreneur Network, founders and their teams connect with other entrepreneurs, experts, mentors, alumni, investors, community leaders, and corporate partners who will help their companies grow. Techstars operates four divisions: Techstars Mentorship-Driven Accelerator Program supercharges success and Techstars Startup Programs inspire, educate, and connect entrepreneurs. Techstars Venture Capital Fund invests in innovative and disruptive companies. Techstars Corporate Innovation Partnerships help brands create products and services. Techstars' accelerator portfolio includes more than 1,000 companies with a market cap of $8.1 billion.

Techstars

Vectr is a venture firm based in Hong Kong. They combine investment, creation and growth to deliver game-changing impact to teams ready to tackle global issues, transform industries and improve the lives of millions.That combines capital, creation and partnership to deliver game-changing impact. We strive to be the ideal partner for founders that are building transformation products and looking to expand their businesses into asia.

Vectr

We back visionary founders who are building technologies of the future. 2048 Ventures is a thesis-driven earliest stage venture capital firm. We are founders, experienced operators, nerds and dreamers obsessed with the future. We've backed over 200 startups and have the experience and conviction to lead your pre-seed or seed round. We get you and your vision before others. We are systems thinkers, engineers, and product junkies. We think about the future non-stop and are ready to understand and back you before anyone else. When we decide to invest, we write you a check and then help you close the rest of the round. We lead rounds with high conviction, and write $500K - $2M checks.

2048 Ventures

Real Ventures is an early-stage venture firm focused on serving daring entrepreneurs with the ambition to create successful, global companies. Since 2007, Real Ventures has dedicated itself to building the Canadian startup ecosystem on the belief that people, not money, build game-changing companies. Real Ventures provides stage-specific guidance, mentorship, and access to networks and resources to fast-track founders’ personal and company growth. Real Ventures manages $325 million across five funds and its active portfolio of 100+ companies is currently valued at $10 billion. www.realventures.com

Real Ventures

We help startups get from prototype to ramen profitable

Ramen Ventures

Panache Ventures is a venture capital firm specializing in pre-seed and seed-stage startup investments. It seeks to invest in sectors that play to Canada’s strengths: artificial intelligence (AI), fintech, digital health, enterprise software, and blockchain.

Panache Ventures

MEDTEQ is a non-profit organization for industrial research and innovation in medical technology. The organization accelerates the development of innovative technological solutions to improve patients’ health and quality of life by mobilizing Canadian talents. They bringing together the key players in healthcare and innovation allows them and their partners, to offer Canadians access to novel solutions. MEDTEQ’s mission is, through collaborative, industry-led projects, to accelerate innovation and position, on a global scale, products and services developed by the Canadian medical technologies industry.

MEDTEQ+

Muse Capital is a female led early stage VC, investing in Consumer Tech with a focus on Underserved Markets. We invest in platforms, products and services across the future of how we care (women’s health, childcare), how we live (wellness and sustainability) and how we play (entertainment, gaming & web 3).  Our superpower is leveraging the founding partners 25+ year expertise in sourcing and executing on business development opportunities for their entrepreneurs, accelerating and operating businesses in both private and public sectors, with their global network of decision makers across F500's, entertainment, sports teams/owners, global investors, and world class tech entrepreneurs.

Muse Capital

Garage Capital is a venture capital firm focused on Canadian companies.

Garage Capital

Rhia Ventures invests in reproductive healthcare solutions that empower women.

Rhia Ventures

Cake Ventures is an investment firm that invests in companies that address the needs of a world undergoing massive demographic changes.  Cake Ventures was founded by Monique Woodard.

Cake Ventures

The Community Fund is a $5 million early-stage fund investing in community-driven companies through an investment partner team. The investment team consists of operators, founders, and investors that bring a wide range of complementary functional and industry expertise. The Community Fund is led by Lolita Taub and Jesse Middleton.

The Community Fund

Leva Capital invests in privately owned businesses within the healthcare sector in Canada, from startups to medium sized companies.

Leva Capital

The $100-million TELUS Pollinator Fund for Good is one of Canada’s largest corporate impact funds, powering the boldest, bravest ideas by for-profit startups that are dedicated to driving social innovation and building tech for good. In support of the UN Sustainable Development Goals, the Fund invests in the next generation of entrepreneurs who are addressing the biggest challenges in health, education, agriculture and the environment – connecting them with the resources and capital they need to grow and thrive. The TELUS Pollinator Fund for Good showcases TELUS’ long-standing commitment to leverage its world leading technology to create meaningful change and make the world a better place.

TELUS Pollinator Fund for Good

RH Capital a Rhia Ventures fund, is an impact-first venture capital firm that invests in early-stage startups with the potential to transform women's health and increase health equity.

RH Capital

Eli is a women's health company on a mission to improve lifelong health by continuously monitoring hormones in saliva. Hormones impact overall health every day and at all stages of life. Yet, traditional testing methods and send-out tests only provide infrequent snapshots. In three simple steps, Eli's at-home technology provides personalized hormone profiles continuously to transform how women manage their hormonal health in key areas like menopause, fertility, contraception, and endocrine conditions.

<div>
 
 Based in Canada, Eli is developing a patent-pending at-home fertility and hormone testing device and complementing app for women. The device, yet to be launched as of January 2021, uses saliva samples and is therefore identified as a hormone-free and non-invasive testing and tracking tool. Since the device provides insights on hormonal profiles, it is not limited to fertility monitoring and can be used throughout different life stages, from puberty to menopause. 
 
 In January 2021, Eli raised seed funding of USD 1.5 million, led by Vectr Ventures. The new funds are to be deployed in product development, obtaining clinical validations, and the first strategic sales. The company also intends to continue working with academic institutions to further women’s health research.
 
</div>

Long-term demographic changes are finally bringing fertility technologies into focus.

Fertility Tech

Eli raises $1.9 million CAD in seed funding to develop at-home hormone monitoring tech | BetaKit

<div>
 
 Glow offers apps that track data related to women’s fertility including ovulation cycle and pregnancy tracking. In addition to apps, the company also offers individualized fertility coaching, clinic identification and community support, and links patients with clinics for procedures such as egg freezing. 
 
 
 Glow generated around USD 0.3 million monthly revenue in October 2020, and as of February 2019 it had around 15 million users, and claims to have helped about 950,000 women get pregnant (from May 2013 to February 2019). In February 2019 Glow partnered with US Match Group (provider of dating products such as Match.com and Tinder), to provide Match’s employees with egg freezing benefits at reputed fertility clinics. In May 2017 it partnered with the National Institute of Health (NIH) to update a prediction model for couples trying to conceive.  
 
 
 In 2020, the company faced investigations into privacy and security failures involving its app. Glow agreed to pay a USD 0.25 million settlement in September 2020.
 
 
 
</div>

Glow

<div>
 
 Inne, based in Germany, offers an at-home mini lab kit for women. Hormone analysis is conducted based on saliva samples. The lab device connects to smartphones for storage and access to the analysis results.
 
 
 Unlike peer offerings, Inne does not attempt to predict future cycles and fertility dates, and instead educates users about their bodies, with information on what changes they should feel in response to the hormonal levels on the day.
 
 
 In May 2022, Inne 
 <a href="https://sp-edge.com/updates/10667?industryIds=40">
 raised USD 10 million
 </a>
 in an extension to its Series A round led by DSM Venturing. The company utilized the funds to continue the development of its mini lab and platform, grow its team, and support its expansion across the US, where it aims to enter with its perimenopause feature, followed by an expanded product launch in late 2022.
 
 
 
</div>

Inne

Proov (formerly known as MFB Fertility) offers the at-home “Proov'' ovulation and progesterone test. Proov tracks hormone levels in urine over multiple days, after suspected ovulation, and estimates whether the progesterone levels are sufficient for implantation, during the 7-10 day implantation window.As of May 2021, it was the only FDA-cleared urine PdG (urine metabolite of the progesterone hormone) test, and its method of determining the fertile window was patented. Moreover, it received the CE marking and expanded its sales footprint to Europe in June 2021.In June 2020, the company received a USD 1.3 million deal from the US Air Force, to provide Proov kits to enrolled individuals. The Proov test was distributed through leading US retailers such as Target and Amazon, and was also used by doctors across the country.Proov raised USD 9.7 million in Series A funding in December 2021, in a round led by Hambrecht Ducera Growth Ventures, with participation from other venture capital firms such as SteelSky Ventures, WCC Partners, and Lightship Capital, among others. The company expects to use the funding to grow its “Complete” product, which includes follicle-stimulating hormone tests and other multi-hormone tests that measure estrone glucuronide, LH and PdG.

Proov

<div>
 
 Progyny works with employers (primarily large enterprises in the US) to optimize the fertility benefits they offer for their employees. It connects employees to fertility specialists and clinics, and also offers extensive support to patients through their Progyny Patient Care Advocates, who provide clinical guidance, education, and emotional support.
 
 
 The company was founded as a fertility education platform and eventually included in vitro fertilization (IVF) referral network Fertility Authority and reproductive health company Auxogyn, into its network. The company pivoted into offering fertility benefit solutions in 2016, and launched Progyny Rx (fertility medication benefit) in 2018.
 
 
 Progyny connects patients to a network of 800 fertility specialists and nearly 600 clinic locations.&nbsp;
 
 
 Key customers and partnerships
 
 
 As of March 2022, the company served 264 enterprise customers (including Facebook, Microsoft, Google, and Nasdaq), and had 3.9 million active members.
 
 
 Funding and financials
 
 
 In October 2019, Progyny raised USD 130 million through its IPO, where it was listed on the Nasdaq.
 
 
 In FY2021, the company reported a revenue of USD 500.6 million reflecting a 45% YoY growth and a net income of USD 65.8 million. The company&rsquo;s revenue for 
 <a href="https://sp-edge.com/updates/14396">
 Q3 FY2022
 </a>
 amounted to USD 205.4 million, representing 68% YoY growth. The management&rsquo;s revenue guidance for FY2022 ranges between USD 775 million and USD 785 million, which implies an YoY growth of 55% to 57%.
 
</div>

Progyny

<div>
 
 Prima Temp offers the artificial intelligence (AI) assisted “Priya” intarvaginal ring sensor and accompanying app to continuously measure a woman’s core body temperature, predicting fertility windows. The app uses big data to improve its predictions, and the app notifies the user of fertile windows. The company also offers the “Kindara” fertility tracking app, which provides fertility related education and links users to a community of over 140,000 members.  
 
 
 The company raised USD 5 million in funding in May 2019 from Gedeon Richter, a Hungarian pharmaceutical company. Although the company primarily focuses on fertility monitoring, it intends to expand its offerings to include other areas of fertility management such as contraception and menopause.  
 
 
 
 
 
</div>

Prima Temp

Test kits which use saliva, blood, or temperature to determine hormone levels and form conclusions on fertility and fertility cycles.


Apps which use data science to identify fertility windows.

Organizations that freeze eggs or embryos for usage at a future date.


Services that analyze sperm samples (via test kit) and/or offer storage facilities for future use.

Companies specializing in supporting patient decision making, financing, clinical visits, physician referrals, and at-home treatments

Offers digital platforms and apps to provide fertility-related support

Uses AI/ML to improve cycle predictions and track symptoms

Some startups use genetic screening to tailor treatment or identify underlying issues

Eli

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless